The experimental injection therapy povetacicept is superior to a placebo at reducing excess protein in urine (proteinuria), a marker…
Articles by Marisa Horak MS
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ultomiris (ravulizumab) to reduce protein in the…
The approved, monthly therapy Voyxact (sibeprenlimab-szsi) can prevent kidney function worsening and kidney failure in adults with immunoglobulin…
Enrollment of people with immunoglobulin A nephropathy (IgAN) in a mid-stage clinical trial testing Jasper Therapeutics’ treatment candidate vensobafusp…
Initial treatment with the approved oral med Filspari (sparsentan) stabilized kidney function among people with immunoglobulin A nephropathy…
Representatives from the American Kidney Fund (AKF) and the IgA Nephropathy Foundation joined dozens of patient advocates on Capitol…
Sefaxersen, an experimental injection therapy given once monthly, reduced protein in the urine, a marker of kidney damage, in…
Treatment with Trutakna (atacicept-vymj) can slow the decline of kidney function in people with immunoglobulin A nephropathy (IgAN),…
Immunoglobulin A nephropathy (IgAN) shares genetic risk factors with many cardiovascular and metabolic conditions, a study found. The findings may…